These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32810546)

  • 1. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
    Patoulias D; Papadopoulos C; Doumas M
    Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
    Kalra S; Bhattacharya S; Kapoor N
    J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Liu M; Hao G
    Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Metab Syndr; 2020; 14(4):347. PubMed ID: 32305776
    [No Abstract]   [Full Text] [Related]  

  • 6. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    Kalyani RR
    N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
    Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B
    Int J Cardiol; 2020 Nov; 318():126-129. PubMed ID: 32569700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
    Kloecker DE; Davies MJ; Khunti K; Zaccardi F
    Diabetes Obes Metab; 2021 Jul; 23(7):1685-1691. PubMed ID: 33764645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
    Volpe M; Gallo G
    Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
    [No Abstract]   [Full Text] [Related]  

  • 14. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Everett BM; Kim SC
    Ann Intern Med; 2022 Jan; 175(1):W4. PubMed ID: 35038405
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2022 Jan; 175(1):W4-W5. PubMed ID: 35038404
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Bepo L; Makam AN; Nguyen OK
    Ann Intern Med; 2022 Jan; 175(1):W3. PubMed ID: 35038403
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Qiu M
    Ann Intern Med; 2022 Jan; 175(1):W3-W4. PubMed ID: 35038402
    [No Abstract]   [Full Text] [Related]  

  • 19. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
    Kim GS; Park JH; Won JC
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.